Elanco Animal Health Incorporated

ELAN

US28414H1032

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-07-17 EDT			5-day change	1st Jan Change
13.05 ^USD	-1.51%		-1.73%	-12.42%

07-09	Merck's Animal Health Division Completes $1.3 Billion Acquisition of Elanco Animal Health's Aqua Business	MT
07-09	Intervet International B.V. completed the acquisition of Assets of Aqua Business from Elanco Animal Health Incorporated.	CI

Elanco Animal Health Incorporated Revises Earnings Guidance for the Fiscal Year 2021

January 26, 2021 at 08:00 am

Elanco Animal Health Incorporated revised earnings guidance for the fiscal year 2021. For the period, the company expects GAAP loss per share from $0.28 to $0.14, to $0.37 to $0.25.

Latest news about Elanco Animal Health Incorporated

Merck's Animal Health Division Completes $1.3 Billion Acquisition of Elanco Animal Health's Aqua Business	07-09	MT
Intervet International B.V. completed the acquisition of Assets of Aqua Business from Elanco Animal Health Incorporated.	07-08	CI
The Veterinary Cooperative Partners with Elanco Animal Health to Elevate Veterinary Care	07-08	CI
Elanco Animal Health Incorporated and Elanco US, Inc Enter into Amendment No. 2 to Its Credit Agreement	07-03	CI
ANALYST RECOMMENDATIONS : Adobe, Nike, Solaredge, Welltower, Spectris...	07-02
Piper Sandler Adjusts Price Target on Elanco Animal Health to $16 From $19, Maintains Neutral Rating	07-01	MT
ANALYST RECOMMENDATIONS : Nvidia, Broadcom, Progressive, Draftkings, Moody's...	07-01
Barclays Cuts Price Target on Elanco Animal Health to $21 From $23, Maintains Overweight Rating	06-28	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Elanco Canine Dermatitis Treatment Will Carry Cautionary Labelling -- Shares Drop	06-27	MT
Elanco Shares Retreat Over Zenrelia Warning Label Concerns	06-27	DJ
Elanco Animal Health Updates US FDA Approval Timelines for Two Drugs; Boosts 2024 Innovation Sales Outlook	06-27	MT
Elanco Provides Innovation Update	06-27	CI
Transcript : Elanco Animal Health Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM	06-11
Transcript : Elanco Animal Health Incorporated Presents at Stifel Jaws & Paws Conference, May-29-2024 08:00 AM	05-29
Elanco Animal Health Says FDA Review Shows Methane-Reducing Cow Feed Additive Meets Rules	05-29	MT
US FDA approves Elanco's feed ingredient to cut methane emissions in dairy cows	05-28	RE
Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements	05-28	MT
Elanco Animal Health Incorporated Announces FDA Completed Review of Bovaer®, First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry	05-28	CI
Piper Sandler Adjusts Price Target on Elanco Animal Health to $19 From $18, Maintains Neutral Rating	05-13	MT
Barclays Raises Elanco Animal Health Price Target to $23 From $19, Maintains Overweight Rating	05-09	MT
BofA Securities Adjusts Price Target on Elanco Animal Health to $20 From $18, Maintains Buy Rating	05-09	MT
Elanco Animal Health Shares Rise as Q1 Earnings, Revenue Beat Estimates	05-08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	05-08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Seek Rate Clues	05-08	MT

Chart Elanco Animal Health Incorporated

Duration

Period

More charts

Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Elanco Animal Health Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.05 USD

Average target price

18.66 USD

Spread / Average Target

+42.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
ELANCO ANIMAL HEALTH INCORPORATED	-12.42%	6.45B
ZOETIS INC.	-7.76%	83.07B
BLUESTAR ADISSEO COMPANY	+35.38%	4B
VIRBAC	-1.67%	3.2B
VIMIAN GROUP AB	+20.44%	1.76B
VETOQUINOL SA	-0.59%	1.3B
JINYU BIO-TECHNOLOGY CO., LTD.	-37.70%	1.03B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-42.92%	952M
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-18.24%	854M
WUHAN KEQIAN BIOLOGY CO.,LTD	-33.66%	865M

Veterinary Drugs